Antengene submits new drug application for selinexor in taiwan for the treatment of three indications in hematologic malignancies

Shanghai  and  hong kong , july 13, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a new drug application (nda) to the taiwan food and drug administration (tfda) for selinexor, a first-in-class xpo1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (xvd), or in combination with dexamethasone (xd) for the treatment of patients with relapsed and/or refractory multiple myeloma (rrmm); and as monotherapy in adult patients with relapsed and/or refractory diffuse large b-cell lymphoma (rrdlbcl), including dlbcl arising from follicular lymphoma, who have received at least two lines of systemic therapy. antengene has submitted new drug applications (ndas) for selinexor in multiple asia pacific markets including china, australia, south korea, and singapore, and was granted priority review status by china's national medical products administration (nmpa) and orphan drug designation by the ministry of food and drug safety of south korea (mfds).
KPTI Ratings Summary
KPTI Quant Ranking